Charles River Laboratories International CRL
NYSE CRL
$282.06 +8.65 (+3.16%)
As of: Sep 17, 2026 · 3:59 PM EDT

Charles River Laboratories International (CRL) Profit After Tax Growth (1y) (2010 - 2026)

Analysis

Charles River Laboratories International (CRL) Profit After Tax Growth (1y) (2010 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (1y) (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn -3.37%
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn 34.46%
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn -64.34%
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn -102.81%
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn 96.48%
6 Evotec SE 574.75 Mn 148.87 Mn - -
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn 4.94%
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn 8.58%
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn 99.80%
10 VivoSim Labs 1.37 Mn 1.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 27, 2026 -102.81%
Mar 28, 2026 -157.36%
Dec 27, 2025 -30.28%
Sep 27, 2025 -20.97%
Jun 28, 2025 -44.10%
Mar 29, 2025 -65.26%
Dec 28, 2024 -213.12%
Sep 28, 2024 -20.14%
Jun 29, 2024 -5.21%
Mar 30, 2024 -28.35%
Dec 30, 2023 -0.08%
Sep 30, 2023 -9.83%
Jul 1, 2023 -10.14%
Apr 1, 2023 9.17%
Dec 31, 2022 35.24%
Sep 24, 2022 -7.18%
Jun 25, 2022 23.07%
Mar 26, 2022 48.94%
Dec 25, 2021 -2.35%
Sep 25, 2021 2.19%